Apogee Therapeutics (APGE) Other Non-Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Other Non-Current Liabilities data on file, last reported at $600000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $600000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $600000.0 (changed N/A YoY) and the FY2025 annual result came in at $2.1 million, up 2000.0% from the prior year.
• Other Non-Current Liabilities slipped to $600000.0 in Q1 2026 per APGE's latest filing, from $2.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $8.0 million in Q4 2022 and bottomed at $100000.0 in Q4 2024.
• The 5-year median for Other Non-Current Liabilities is $2.1 million (2025), against an average of $3.0 million.
• The widest annual swing landed in 2024, when Other Non-Current Liabilities slumped 98.08%; it then surged 2000.0% in 2025.
• Tracing APGE's Other Non-Current Liabilities over 5 years: stood at $8.0 million in 2022, then sank by 35.0% to $5.2 million in 2023, then tumbled by 98.08% to $100000.0 in 2024, then surged by 2000.0% to $2.1 million in 2025, then slumped by 71.43% to $600000.0 in 2026.
• Per Business Quant, the three latest APGE Other Non-Current Liabilities figures stand at $600000.0 (Q1 2026), $2.1 million (Q4 2025), and $100000.0 (Q2 2025).

Peer Comparison